Atlantis Investment Management
35/F The Centrium 60 Wyndham Street, Central, Hong Kong Island, Hong Kong
Overview
Atlantis Investment Management is dedicated exclusively to Asian equity strategies. Its two main investment focuses, China and Asia ex-Japan, are operated independently and led by its dedicated portfolio managers. The firm was founded in London in 1994 by three-star ex-Schroders fund managers. Ms. Yang Liu, now Atlantis’ Chairperson and Chief Investment Officer, joined Atlantis in 2002 as a fund manager.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- Stealth BioTherapeutics
Participated · Convertible Note · Jun 2018
Stealth BioTherapeutics focuses on developing therapies that directly address mitochondrial bioenergetic deficits across rare and age-related diseases. The company’s development portfolio includes elamipretide programs in Barth syndrome, polymerase gamma–related mitochondrial disease and dry age-related macular degeneration, a next-generation clinical candidate bevemipretide for ophthalmic and neurological indications, and preclinical assets SBT-255 and SBT-589 for rare mitochondrial disorders. Its parent, Mighty Therapeutics, achieved FDA approval in September 2025 for the first commercial therapy for Barth syndrome and the first FDA-approved therapy to directly target mitochondria, generating revenue from its lead commercial product. The company plans to use newly secured capital to accelerate commercial launch activities and advance late-stage and pipeline development programs. Financially, current cash, cash equivalents and product revenues are expected to extend runway into 2028, with additional financing drawdowns projected to support cash flow positivity in early 2029.
Team
No current team members are available.